News Search Results
Mar 05, 2024, 00:32 ET Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, and AnHeart Therapeutics ("AnHeart"), a global clinical-stage biopharmaceutical company developing novel precision therapies
More news about: Innovent Biologics
Mar 04, 2024, 17:55 ET Formosa Pharmaceuticals and AimMax Therapeutics Receive FDA Approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery
Pharmaceuticals, Inc. Formosa Pharmaceuticals, Inc. (6838.TWO) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT™) improves the dissolution and bioavailability of APIs for topical,
More news about: Formosa Pharmaceuticals
Mar 04, 2024, 09:50 ET PMB Project Named 2023 HREI Insights™ Award Winner
maternal fetal testing, pelvic health & rehab, perinatal education, OB/GYN clinical offices, women's mental health services, hematology oncology, ophthalmology, gastroenterology, orthopedics, and conference / education rooms, and a Blue Bowl Superfoods outlet. Visitors and tenants also will have access
More news about: PMB
Mar 04, 2024, 08:30 ET InMode to Present at March Investor Conferences and Events
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
More news about: InMode LTD
Mar 04, 2024, 08:00 ET SECTRA'S ENTERPRISE IMAGING SOLUTION NOW COVERS MAJORITY OF MIDWEST PATIENTS FOLLOWING NEW CONTRACT
systems worldwide. Sectra offers a complete enterprise solution comprised of imaging modules (radiology, cardiology, pathology, orthopedics, and ophthalmology), and a robust VNA. Over the last consecutive eleven years, Sectra has been awarded Best in KLAS for highest customer satisfaction. For more information,
More news about: Sectra
Mar 04, 2024, 06:45 ET Mallinckrodt Announces Appointment of Paul O'Neill as Executive Vice President, Quality & Operations, Specialty Brands
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics
More news about: Mallinckrodt plc
Mar 01, 2024, 08:50 ET Mallinckrodt Announces U.S. FDA Approval of Supplemental New Drug Application for Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics
More news about: Mallinckrodt plc
Feb 29, 2024, 19:00 ET Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia
biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been dosed in Australia in a first-in-human
More news about: Innovent Biologics
Feb 29, 2024, 06:00 ET Cardinal Health annual research report examines milestone year in biosimilars
remaining barriers to widespread uptake. With 2024 expected to be a critical year for retina biosimilars, Cardinal Health surveyed providers in ophthalmology to obtain perspectives that may influence adoption while highlighting continued obstacles to wider use of biosimilars. Nearly 80% of survey participants
More news about: Cardinal Health
Feb 28, 2024, 01:00 ET Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration
long term. Smith continued: "As I have said previously, in addition to continuing to develop the three core therapeutic areas that we identified—ophthalmology, dermatology and GI—we are also going to be opportunistic in seeking out assets that we believe fit our company well and have the potential
More news about: Viatris Inc.
Feb 25, 2024, 13:00 ET Groundbreaking! Phase II Data of LP-003 Unveiled by Longbio Pharma at AAAAI2024
"Longbio Pharma"), a leading biotech company dedicated to developing innovative protein treatments for allergy, respiratory, dermatology, hematology, ophthalmology, and other autoimmune and rare diseases, proudly announced the release of preliminary Phase II data for LP-003, the new generation anti-IgE antibody,
More news about: Longbio Pharma
Feb 22, 2024, 15:45 ET The Inner Circle Acknowledges, Joshua Cohen as a Top Pinnacle Life Member
The Inner Circle, Joshua Cohen is acknowledged as a Top Pinnacle Life Member for his contributions to the field of Ophthalmology. Dr. Cohen pursued his prestigious education at Harvard University where he earned a Bachelor of Science degree.
More news about: The Inner Circle
Feb 22, 2024, 14:00 ET MEMS in the Global Medical Market: New Report with 2020-2023 Data, CAGR Projections to 2028 and Profiles of Leading Players TE Connectivity, STMicroelectronics, Teledyne Dalsa and Silex Microsystems
future growth include drug delivery devices, devices for medical research (especially genomics, cellular analysis and high throughput), cardiology, ophthalmology, endocrinology, in vitro diagnostics and tissue regeneration. Drug delivery systems (DDS) based on organic, inorganic and hybrid nanoparticles
More news about: Research and Markets
Feb 22, 2024, 08:00 ET ReFocus Eye Health Strengthens Presence in New Jersey with Eight Premier Practice Partnerships
Feb. 22, 2024 /PRNewswire/ -- ReFocus Eye Health proudly announces its latest expansion with the addition of eight distinguished ophthalmology practices across northern New Jersey. This newly formed partnership represents a transformational milestone for
More news about: ReFocus Eye Health
Feb 21, 2024, 13:12 ET Console & Associates, P.C.: American Vision Partners Reports Data Breach Exposing SSNs and Medical Information of 2.3 Million
affecting patients nationwide. However, victims of the breach may not be familiar with the name American Vision Partners because it works with ophthalmology practices in a behind-the-scenes role. Thus, it's possible American Vision Partners has information about patients who were entirely unaware that
More news about: Console & Associates, P.C.
Feb 21, 2024, 08:37 ET New Study Publication Demonstrates Eye Health and Cognitive Benefits of Lutein and Zeaxanthin from Lutemax Kids
American Academy of Ophthalmology (A.A.O.) recommends dark leafy greens because of the higher concentration of lutein. Unfortunately, only one in ten parents say their children
More news about: Omniactive Health Technologies
Feb 21, 2024, 03:00 ET Polpharma Biologics' investigational biosimilar shows PK/PD comparability to inflammatory bowel disease blockbuster Entyvio®
focused on broadening access to biological medicines used to treat some of the world's most impactful diseases across neurology, immunology, and ophthalmology. The company is at the forefront of the next wave in biopharma, leveraging its knowledge, capabilities, and footprint to develop its robust pipeline
More news about: Polpharma Biologics
Feb 20, 2024, 11:36 ET Richard F. Spaide, MD of the Vitreous Retina Macula Consultants of New York Awarded the Arnall Patz Medal by the Macula Society
angiography, and new computer-based rendering techniques to visualize retinal anatomy. He is a Fellow of the Association for Research and Vision in Ophthalmology. About Vitreous Retina Macula Consultants of New YorkThe group of ophthalmologists at Vitreous
More news about: Vitreous Retina Macula Consultants of New York
Feb 19, 2024, 19:21 ET Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA
Diseases, Chinese Ophthalmology Branch, Chinese Medical Association; Group of Thyroid Diseases, Chinese Endocrinology Branch, Chinese Medical Association. Chinese Guidelines for the Diagnosis and Treatment of Thyroid Associated Ophthalmopathy (2022). Chinese Journal of Ophthalmology. 2022; 58 (9).
More news about: Innovent Biologics
Feb 19, 2024, 19:00 ET 信達生物宣佈IBI311（抗IGF-1R抗體）治療甲狀腺眼病的III期臨床研究（RESTORE-1）達成主要終點，計劃將遞交上市申請
、法律和社會情況的未來變化及發展的影響，實際結果可能會與前瞻性表述所含資料有較大差別。 參考文獻： 1. Bartley G. The epidemiological characteristics and clinical course of ophthalmology associated with autoimmune thyroid disease in Olmsted Country, Minnesota. Trans Am Ophthalmol Soc 1994;92:477-588.
More news about: 信達生物
Feb 19, 2024, 09:00 ET AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis
company dedicated to developing and commercializing transformative pharmaceutical, and surgical products that address critical unmet medical needs in ophthalmology, today announced that the Singapore Health Sciences Authority (HSA) has accepted its New Drug Application (NDA) for DEXTENZA® (0.4 mg dexamethasone
More news about: AffaMed Therapeutics
Feb 19, 2024, 06:30 ET Neurophth Announces Completion of Patient Enrollment for Opvika® Phase I/II Clinical Trial in the U.S.
patients suffering from genetic diseases globally. Our validated AAV platform, which has been published in Nature - Scientific Reports, Ophthalmology, and EBioMedicine, has successfully delivered proof-of-concept investigator-initiated trials data of 186 subjects with investigational
More news about: Neurophth Therapeutics, Inc.
Feb 19, 2024, 06:25 ET Skin Excision Market to Reach $59.14 Billion by 2031 Owing to Increasing Prevalence of Skin Cancers and Advanced Healthcare Infrastructure | Says Coherent Market Insights
Market, By Product Type (Consumables, Devices, Software, Services, and Others), By Application (Cardiology, Orthopedics, Obstetrics/Gynecology, Ophthalmology, Gastroenterology, and Others), By Distribution Channel (Direct Tender, Retail Sales, and Online Sales), By Geography (North
More news about: Coherent Market Insights
Feb 16, 2024, 17:30 ET Global Intraocular Lens Market Report 2024: Market to Grow from $4.23 Billion in 2023 to $6.11 Billion by 2030 - Rising Incidence of Myopia and Diabetes Boosts Demand
essential worldwide locations are also anticipated to expand market throughout the forecast period. According to the American Academy of Ophthalmology, myopia influences an estimated 25% of Americans, making it a vast and well-known disorder. Furthermore, high myopia can cause doubtlessly blinding
More news about: Research and Markets
Feb 14, 2024, 16:15 ET SightGlass Vision Receives Breakthrough Device Designation from U.S. Food and Drug Administration
Diffusion Optics Technology™ spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). British Journal of Ophthalmology Published Online First: 01 September 2022. DOI: 10.1136/bjo-2021-321005 4 Rappon J., et al. Two-year
More news about: SightGlass Vision